Pharmaceuticals News and Research

RSS

Forest, Alkem and Torrent settle generic BYSTOLIC patent infringement litigation

Forest Laboratories, Inc. and Forest Laboratories Holdings, Ltd. announced today that they have entered into settlement agreements with Alkem Laboratories, Ltd., Indchemie Health Specialties Pvt. Ltd., and Torrent Pharmaceuticals Ltd. and Torrent Pharma Inc. in patent infringement litigation brought by Forest in response to abbreviated new drug applications (ANDAs) filed by Alkem, Indchemie and Torrent each seeking approval to market generic versions of Forest's BYSTOLIC (nebivolol) tablets.

29 Nov 2012

Solvias, Hovione partner to develop and supply pharmaceutical co-crystals

Hovione and Solvias today announced the establishment of a collaboration focused on the development and GMP supply of pharmaceutical co-crystals. This strengthens Hovione's expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, with Solvias' excellence in solid state chemistry.

28 Nov 2012

Researchers discover alternative mechanism for Ras protein activation

The protein Ras plays an important role in cellular growth control. Researchers have focused on the protein because mutations in its gene are found in more than 30 percent of all cancers, making it the most prevalent human oncogene.

28 Nov 2012

Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

Bayer's BAY 86-6150 is being investigated in a Phase II/III study called TRUST (TReatment with Unique recombinant rFVIIa STudy), and the recruitment of the first cohort is now complete.

28 Nov 2012

Florbetapir PET scans can detect brain amyloid deposits associated with Alzheimer’s

A test to detect brain amyloid deposits associated with Alzheimer disease (AD) provides doctors with useful information on treatment and further testing for patients with cognitive impairment, according to a study published online by the journal Alzheimer Disease & Associated Disorders.

28 Nov 2012

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

Merrimack Pharmaceuticals, Inc. today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.

28 Nov 2012

FDA grants final approval to Cobrek’s generic Luxiq foam NDA for treatment of scalp psoriasis

Perrigo Company today announced that its partner, Cobrek Pharmaceuticals, Inc., received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam.

28 Nov 2012

Walden University announces recipients of six Nurses of the Year scholarships

Walden University today announced the recipients of six Nurses of the Year scholarships. The scholarships were awarded to nurses who are making a positive difference in the lives of their patients, in their organizations and to the future of nursing.

28 Nov 2012

Study identifies gene signature associated with resistance to cancer therapies

Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced the publication in the November 21st issue of the prestigious scientific journal "Cell" of a study that identifies a gene signature that is associated with resistance to a broad range of cancer therapies in multiple cancer types.

28 Nov 2012

Big pharma and federal government predicted to play diminishing role in research funding

In a commentary to be published in the Dec. 12 issue of The Journal of the American Medical Association, two Johns Hopkins faculty members predict an ever-diminishing role for government and drug company funding of basic biomedical research and suggest scientists look to “innovative” kinds of private investment for future resources.

27 Nov 2012

Amarantus demonstrates excellent diffusion profile of MANF in the striatum of rat brains

Amarantus BioSciences, Inc., a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

27 Nov 2012

National Taiwan University Hospital, PAREXEL establish alliance

PAREXEL International Corporation a leading global biopharmaceutical services provider, and the National Taiwan University Hospital (NTUH) announced today that they have established an alliance. Under the agreement, PAREXEL and NTUH will collaborate to provide drug development services in Taiwan.

From Parexel 27 Nov 2012

Specific combination of two pharmaceutical substances show promise against multiple sclerosis

A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer and Dr. Frank Striggow have combined two already approved pharmaceutical substances with each other using a chemical linker structure.

27 Nov 2012

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease is a very broad family of diseases. There are two main categories of liver disease:

27 Nov 2012

Recognizing pharmaceutical philanthropy's role in fighting NTDs

"In October 1987, Roy Vagelos, then the chief executive of pharmaceutical company Merck, launched the largest pharmaco-philanthropic venture ever," William Foege, an epidemiologist and former director of the CDC, writes in a Washington Post opinion piece highlighting the company's efforts to combat onchocerciasis in the developing world through the free distribution of its drug Mectizan.

27 Nov 2012

EC approves Regeneron’s EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).

27 Nov 2012

Patheon announces cash tender offer for all outstanding 8.625% Senior Secured Notes

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it is commencing a cash tender offer for any and all of its outstanding 8.625% Senior Secured Notes due 2017 (CUSIP Numbers 70319W AA6 (Rule 144A) and C7197E AA2 (Regulation S)), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated the date hereof, and in the related Letter of Transmittal.

27 Nov 2012

XTL Biopharmaceuticals purchases 4,620,356 shares of Proteologics from Teva

XTL Biopharmaceuticals Ltd., a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium).

27 Nov 2012

Drug development pipeline sometimes involves intersection of influence, research and profits

[S]ince about the mid-1980s, research funding by pharmaceutical firms has exceeded what the National Institutes of Health spends.

26 Nov 2012

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 "Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies".

26 Nov 2012

Pharmaceuticals News and Research

Forest, Alkem and Torrent settle generic BYSTOLIC patent infringement litigation

Solvias, Hovione partner to develop and supply pharmaceutical co-crystals

Researchers discover alternative mechanism for Ras protein activation

Bayer completes recruitment of first cohort for BAY 86-6150 Phase II/III study in hemophilia

Florbetapir PET scans can detect brain amyloid deposits associated with Alzheimer’s

Merrimack’s MM-302 Phase I results and MM-DX-929 preclinical data to be presented at SABCS

FDA grants final approval to Cobrek’s generic Luxiq foam NDA for treatment of scalp psoriasis

Walden University announces recipients of six Nurses of the Year scholarships

Study identifies gene signature associated with resistance to cancer therapies

Big pharma and federal government predicted to play diminishing role in research funding

Amarantus demonstrates excellent diffusion profile of MANF in the striatum of rat brains

National Taiwan University Hospital, PAREXEL establish alliance

Specific combination of two pharmaceutical substances show promise against multiple sclerosis

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Recognizing pharmaceutical philanthropy's role in fighting NTDs

EC approves Regeneron’s EYLEA for treatment of wet AMD

Patheon announces cash tender offer for all outstanding 8.625% Senior Secured Notes

XTL Biopharmaceuticals purchases 4,620,356 shares of Proteologics from Teva

Drug development pipeline sometimes involves intersection of influence, research and profits

USPTO grants patent for galactomannan-based carbohydrate galectin inhibitor compounds

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence